Staidson Beijing Biopharma Return on Common Equity

The following section summarizes insights on Staidson Beijing Biopharma's Return on Common Equity:

• Staidson Beijing Biopharma's latest twelve months return on common equity is -14.9%
• Staidson Beijing Biopharma's return on common equity for fiscal years ending December 2020 to 2024 averaged -15.8%.
• Staidson Beijing Biopharma's operated at median return on common equity of -13.6% from fiscal years ending December 2020 to 2024.
• Looking back at the last 5 years, Staidson Beijing Biopharma's return on common equity peaked in December 2020 at -8.3%.
• Staidson Beijing Biopharma's return on common equity hit its 5-year low in December 2023 of -33.6%.
• Staidson Beijing Biopharma's return on common equity decreased in 2020 (-8.3%, -718.8%), 2021 (-8.8%, +6.1%), 2023 (-13.6%, +54.9%), and 2023 (-33.6%, +147.7%) and increased in 2024 (-14.9%, -55.8%).